View of Clinical Outcomes after Switching from Originator Infliximab to the Biosimilar Ixifi in Patients with Axial Spondyloarthritis: A Single-Center Study from Türkiye | Rheumatology (Bulgaria)

← Clinical Outcomes after Switching from Originator Infliximab to the Biosimilar Ixifi in Patients with Axial Spondyloarthritis: A Single-Center Study from Türkiye